Agenus Inc (AGEN)
10.44
-1.27
(-10.85%)
USD |
NASDAQ |
May 10, 16:00
10.44
0.00 (0.00%)
After-Hours: 18:24
Agenus Research and Development Expense (Quarterly)
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2011 | 2.528M |
| June 30, 2011 | 2.824M |
| March 31, 2011 | 2.815M |
| December 31, 2010 | |
| September 30, 2010 | 2.822M |
| June 30, 2010 | 2.629M |
| March 31, 2010 | 4.631M |
| December 31, 2009 | 3.222M |
| September 30, 2009 | 3.747M |
| June 30, 2009 | 5.028M |
| March 31, 2009 | 4.905M |
| December 31, 2008 | 3.698M |
| September 30, 2008 | 5.396M |
| June 30, 2008 | 5.839M |
| March 31, 2008 | 5.731M |
| December 31, 2007 | 3.643M |
| September 30, 2007 | 6.133M |
| June 30, 2007 | 6.051M |
| March 31, 2007 | 5.962M |
| December 31, 2006 | 6.016M |
| September 30, 2006 | 6.252M |
| June 30, 2006 | 7.866M |
| March 31, 2006 | 8.840M |
| December 31, 2005 | 10.23M |
| Date | Value |
|---|---|
| September 30, 2005 | 11.99M |
| June 30, 2005 | 13.09M |
| March 31, 2005 | 11.30M |
| December 31, 2004 | 10.08M |
| September 30, 2004 | 9.816M |
| June 30, 2004 | 10.88M |
| March 31, 2004 | 10.95M |
| December 31, 2003 | 10.57M |
| September 30, 2003 | 13.40M |
| June 30, 2003 | 11.76M |
| March 31, 2003 | 10.32M |
| December 31, 2002 | 11.50M |
| September 30, 2002 | 10.36M |
| June 30, 2002 | 9.957M |
| March 31, 2002 | 8.171M |
| December 31, 2001 | -22.68M |
| September 30, 2001 | 41.42M |
| June 30, 2001 | 6.458M |
| March 31, 2001 | 6.168M |
| December 31, 2000 | 5.888M |
| September 30, 2000 | 4.498M |
| June 30, 2000 | 3.821M |
| March 31, 2000 | 3.368M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Protalix BioTherapeutics Inc | 3.102M |
| InfuSystems Holdings Inc | -- |
| PAVmed Inc | 3.595M |
| Allogene Therapeutics Inc | 54.66M |
| Pfizer Inc | 2.493B |